CD274 and neoplasm: The inhibition of these receptors led to the development of multiple immunotherapy bioengineered agents, some of which block PD-1 and CTLA-4 on T cells and others of which block the PD-1 ligand PD-L1 on tumor cells leading the immune system to recognize cancer cells and destroy them.